In the premarket trading session, at last check, Obalon Therapeutics Inc. (OBLN) stock had surged by 6.48% to $3.12. OBLN stock previously closed session at $2.93. The stock volume traded 7.17 million shares. In the past year up-to-date OBLN shares had jumped by 285.53%. In the past week the shares saw a surge of 19.59%. In the past three and six months, the stock shed-37.26% and had added 225.56% respectively. Furthermore, Obalon Therapeutics is currently valued in the market at $26.90 million and the outstanding shares of the company total to a 7.77 million shares.
Law firms and attorneys are investigating Obalon Therapeutics
As of late this previous month, on 23rd April 2021, WeissLAW LLP reminded OBLN investors that it has aongoing investigation concerning Obalon Therapeutics Inc. what’s more, is subsequently urgingOBLN stock shareholders to talk about this investigation with the firm to know their privileges.
On 21st January 2021, a law office called WeissLaw LLP declared that it was beginning an investigation on the potential breaches of fiduciary duties and different infringement of law by Board of Directors in Obalon Therapeutics Inc.
The potential breaches suggest if whether the organization acted to the greatest benefit of Obalon’s public shareholders when choosing for this proposed merger and if so does the acquisition understanding adequately repay the investors of OBLN stock.
On twentieth January 2021, Obalon Therapeutics Inc. reported a consent to converge with another weight reduction organization by the name of ReShapeLifesciences Inc. The news caused OBLN stock to take off by six-hold in volume exchanging and rose by 503.4% in cost.
Financial update on the OBLN stock
The company had overall seen a drop in its revenue for the full year and fourth quarter 2020 because of suspension of work and operations in the second quarter 2020 primarily.
The company reported $0.1 million in Q4 and $1.6 million in Full Year 2020 as compared to $0.8 million in Q4 2019 and $3.3 million in Full Year 2019. The company did report $0 for the fourth quarter of 2020 and $1.0 million for the full year compared to the $0.6 million for Q4 2019 and $3.0 million in Full Year 2019.
The operating loss that incurred in the Q4 2020 was $3.6 million lower than the $5.0 million of Q4 in 2019.
OBLN stock is strapped up on cash equivalents and cash of $3.9 million which the company may quite possibly use for general proceeds of capital funding and operations.
Obalon Therapeutics, Inc. is a technology company which is specifically based on a vertically integrated medical technology structure. It was founded in 2008 and the HQ is established in Carlsbad, California. The Company focuses on the development and commercialization of medical devices that are differentiated for treating people with weight problems and obesity. The company had three retail treatment centers in California, as of 27th February 2020.